Copyright
©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1667-1677
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1667
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1667
The test arm (n = 24) | The control arm (n = 16) | P value | |
Body mass index, kg/m2 | -0.2 (-0.9-1.5) | 0.0 (0.0-0.5) | 0.281 |
Child–Pugh score | -1.5 [-3.0-(-0.5)] | 0 (-0.5-1.5) | 0.001 |
Child–Pugh class (from B or C to A), n (%) | 8 (33.3) | 1 (6.3) | 0.048 |
End-diastolic volume of the left ventricle, mL | -13 [-17-(-10)] | 0 (-3-12) | < 0.001 |
Ejection fraction of the left ventricle, % | 0.5 (-0.7-0.3) | 0.0 (0.0-0.3) | 0.590 |
Stroke volume, mL | -7 [-12-(-4)] | 0 (-3-8) | < 0.001 |
Heart rate, bpm | 2 (-4-8) | -2 (-7-7) | 0.234 |
Cardiac output, L/min | -0.5 [-1.0-(-0.1)] | 0.3 (-0.3-0.9) | 0.026 |
Mean blood pressure, mmHg | 1.8 (-1.7-7.5) | 3.8 (-3.3-15.3) | 0.847 |
Systemic vascular resistance, dyn· s· cm−5 | 237 (39-358) | 30 (-200-227) | 0.026 |
Mean pulmonary artery pressure, mmHg | 0.0 (-2.1-0.6) | 1.2 (0.0-1.8) | 0.043 |
Esophageal varices, a decrease in grade, n (%) | 2 (4.3) | 0 | 0.354 |
Esophageal varices, an increase in grade, n (%) | 0 | 0 | - |
Regression hepatic encephalopathy, n (%) | 8 (33.3) | 1 (6.3) | 0,048 |
Ascites, a decrease in degree, n (%) | 15 (62.4) | 4 (25.0) | 0.022 |
Ascites, an increase in degree, n (%) | 1 (4.2) | 3 (18.8) | 0.167 |
Red blood cells as 1012 cell/L | 0.2 (-0.1-0.5) | 0.2 (-0.1-0.4) | 0.730 |
White blood cells as 109 cell/L | 0.1 (-1.2-0.6) | -0.1 (-2.1-0.7) | 0.782 |
Platelets as 109 cell/ L | 11 (4-32) | -6 (-14-1) | < 0.001 |
Serum total protein, g/L | -0.2 (-4.2-8.9) | -1.4 (-3.5-5.6) | 0.793 |
Serum albumin, g/L | 3.0 (0.6-7.7) | -3.1 (-5.1-2.4) | 0.001 |
Serum total bilirubin, μmol/L | -5.1 [-23.9-(-0.9)] | -3.7 (-10.0-17.2) | 0.181 |
International normalized ratio | 0.0 (-0.1-0.1) | 0.0 (-1.0-0.1) | 0.544 |
Serum cholesterol, mmol/L | 0.2 (-0.4-1.2) | 0.5 (-1.0-2.0) | 0.571 |
Serum triglyceride, mmol/L | 0.1 (-0.2-0.2) | 0.1 (-0.6-0.4) | 0.836 |
Serum creatinine, mg/dL | 2.4 (-9.1-8.1) | -3.5 (-11.2-4.2) | 0.264 |
Serum sodium, mmol/L | 1.5 (0.5-3.0) | -1 (-3-2) | 0.048 |
Serum potassium, mmol/L | 0.0 (-0.4-1.2) | 0.1 (-0.2-0.3) | 0.523 |
Serum glucose, mmol/L | 0.4 (-0.1-0.7) | 0.0 (-0.9-0.8) | 0.423 |
Alanine aminotransferase, U/L | -1 (-15-6) | 2 (-15-8) | 0.740 |
Aspartate aminotransferase, U/L | -9 (-32-1) | -2 (-26-20) | 0.116 |
Gamma glutamyl transferase, U/L | -8 (-171-11) | 6 (-15-23) | 0.039 |
Alkaline phosphatase, U/L | -40 (-95-3) | 26 (-57-91) | 0.016 |
Cholinesterase, U/L | 257 (28-734) | -155 [-239-(-68)] | 0.016 |
C-reactive protein, mg/L | -3.0 [-4.5-(-0.5)] | 1.0 (-2.0-4.5) | 0.044 |
- Citation: Maslennikov R, Efremova I, Ivashkin V, Zharkova M, Poluektova E, Shirokova E, Ivashkin K. Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial. World J Hepatol 2022; 14(8): 1667-1677
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1667.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1667